| pubmed-article:2704231 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2704231 | lifeskim:mentions | umls-concept:C0439849 | lld:lifeskim |
| pubmed-article:2704231 | lifeskim:mentions | umls-concept:C0178539 | lld:lifeskim |
| pubmed-article:2704231 | lifeskim:mentions | umls-concept:C1513095 | lld:lifeskim |
| pubmed-article:2704231 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
| pubmed-article:2704231 | lifeskim:mentions | umls-concept:C0073192 | lld:lifeskim |
| pubmed-article:2704231 | lifeskim:mentions | umls-concept:C0004565 | lld:lifeskim |
| pubmed-article:2704231 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2704231 | pubmed:dateCreated | 1989-5-16 | lld:pubmed |
| pubmed-article:2704231 | pubmed:abstractText | Rhodamine 123 (R123) is a mitochondria-specific prototype anticancer agent because its target is the energy-producing mechanism of the cell. The goal of this study was to investigate the relationship between intracellular R123 accumulation and cytotoxicity in a R123-sensitive cell line (RS) and a R123-resistant subline (RR) that we developed. Cytotoxicity after exposure to R123 (0-60 micrograms/ml) was assessed using the clonogenic assay. Intracellular R123 was extracted with acid-alcohol and measured by fluorimetry. The rate of R123 accumulation over 1 hr was significantly higher (P less than 0.0001) for RS cells (4.65 +/- 0.39 micrograms/min/10(6) cells) than for RR cells (1.29 +/- 0.24 micrograms/min/10(6) cells). R123 accumulation in RS cells was strongly correlated (r = 0.80; P less than 0.0001) with cytotoxicity. Treatment of RR cells with verapamil (100 microM) reversed R123 resistance. The resulting dose-survival curve was identical to the dose-response curve of RS cells treated with R123 alone. Cellular content of R123 in RR cells treated with verapamil increased to a level similar to that of RS cells and correlated with cytotoxicity. These data suggest that cytotoxicity of R123 in B16 cells results from increased cellular accumulation of R123. | lld:pubmed |
| pubmed-article:2704231 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2704231 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2704231 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2704231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2704231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2704231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2704231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2704231 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2704231 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2704231 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2704231 | pubmed:issn | 0022-4804 | lld:pubmed |
| pubmed-article:2704231 | pubmed:author | pubmed-author:GayGG | lld:pubmed |
| pubmed-article:2704231 | pubmed:author | pubmed-author:TejS CSC | lld:pubmed |
| pubmed-article:2704231 | pubmed:author | pubmed-author:KragD NDN | lld:pubmed |
| pubmed-article:2704231 | pubmed:author | pubmed-author:WardellJJ | lld:pubmed |
| pubmed-article:2704231 | pubmed:author | pubmed-author:TheonA PAP | lld:pubmed |
| pubmed-article:2704231 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2704231 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:2704231 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2704231 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2704231 | pubmed:pagination | 361-5 | lld:pubmed |
| pubmed-article:2704231 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:meshHeading | pubmed-meshheading:2704231-... | lld:pubmed |
| pubmed-article:2704231 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2704231 | pubmed:articleTitle | Relationship between cellular accumulation of rhodamine 123 (R123) and cytotoxicity in B16 melanoma cells. | lld:pubmed |
| pubmed-article:2704231 | pubmed:affiliation | Department of Surgery, University of California, Davis, School of Medicine, Sacramento 95817. | lld:pubmed |
| pubmed-article:2704231 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2704231 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
